AZD1390 Clinical Trials

Size	Price	Qty
2mg	USD 147
5mg	USD 217

Clinical Trials

AZD1390 is being evaluated across several clinical trials ranging from Early Phase 1 through Phase 3 to assess safety, pharmacokinetics, and combination regimens with radiotherapy. These studies target central nervous system malignancies, including glioblastoma and leptomeningeal disease, advanced solid tumors such as non-small cell lung cancer, and healthy volunteers. Led by AstraZeneca in collaboration with academic institutions and research coalitions, trial recruitment statuses currently range from actively recruiting to completed.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03970447	RECRUITING	Glioblastoma	Global Coalition for Adaptive Research	2019-07-30	PHASE2; PHASE3
NCT05678010	ACTIVE_NOT_RECRUITING	Solid Tumor; Metastatic Solid Tumor; Solid Carcinoma; Solid Tumor, Adult; Metastatic Tumor; Metastatic Cancer	Memorial Sloan Kettering Cancer Center	2023-05-17	PHASE1
NCT07643870	NOT_YET_RECRUITING	Advanced Solid Malignancies	AstraZeneca	2026-06-30	PHASE1
NCT06894979	ACTIVE_NOT_RECRUITING	Childhood Astrocytoma; Childhood Diffuse Intrinsic Pontine Glioma; Childhood Diffuse Midline Glioma; Childhood Glioblastoma; Childhood Malignant Glioma	Children's Oncology Group	2025-06-18	PHASE1
NCT03423628	ACTIVE_NOT_RECRUITING	Recurrent Glioblastoma Multiforme; Primary Glioblastoma Multiforme; Brain Neoplasms, Malignant; Leptomeningeal Disease (LMD)	AstraZeneca	2018-04-02	PHASE1
NCT05182905	ACTIVE_NOT_RECRUITING	Glioblastoma; Glioma; Glioblastoma Multiforme; Glioma, Malignant	Nader Sanai	2022-05-27	EARLY_PHASE1
NCT04550104	RECRUITING	Non Small Cell Lung Cancer	University of Leeds	2021-03-17	PHASE1
NCT05116254	TERMINATED	Soft Tissue Sarcoma Adult	The Netherlands Cancer Institute	2022-07-18	PHASE1
NCT05182905	Recruiting	Glioblastoma\|Glioma\|Glioblastoma Multiforme\|Glioma Malignant	Nader Sanai\|Barrow Neurological Institute\|Ivy Brain Tumor Center\|AstraZeneca\|St. Joseph''s Hospital and Medical Center Phoenix	2022-03-09	Early Phase 1
NCT03423628	Recruiting	Recurrent Glioblastoma Multiforme\|Primary Glioblastoma Multiforme\|Brain Neoplasms Malignant\|Leptomeningeal Disease (LMD)	AstraZeneca	2018-04-02	Phase 1
NCT03215381	COMPLETED	Healthy Volunteer Male Subjects	AstraZeneca	2017-10-10	PHASE1
NCT03215381	Completed	Healthy Volunteer Male Subjects	AstraZeneca\|Karolinska Institutet Quintiles IMS	2017-10-10	Phase 1

(data from https://clinicaltrials.gov, updated on 2026-07-30)

Check the AZD1390 product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

AZD1390 acts as a potent, central nervous system-penetrant inhibitor of ataxia telangiectasia mutated kinase, target-binding to block downstream phosphorylation of key DNA repair signaling proteins and disrupting double-strand break resolution in dividing cancer cells. By compromising DNA damage recovery cascades, this inhibition significantly sensitizes glioblastoma and other solid tumor cells to radiation-induced DNA damage, thereby enhancing radiosensitivity and promoting tumor regression in clinical settings.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).